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Abstract Cell-surface CD25 expression is critical for maintaining immune function and
homeostasis. As in few reported cases, CD25 deficiency manifests with severe autoimmune
enteritis and viral infections. To dissect the underlying immunological mechanisms driving these
symptoms, we analyzed the regulatory and effector T cell functions in a CD25 deficient patient
harboring a novel IL2RA mutation. Pronounced lymphoproliferation, mainly of the CD8+ T cells,
was detected together with an increase in T cell activation markers and elevated serum
cytokines. However, Ag-specific responses were impaired in vivo and in vitro. Activated
CD8+STAT5+ T cells with lytic potential infiltrated the skin, even though FOXP3+ Tregs were
present and maintained a higher capacity to respond to IL-2 compared to other T-cell subsets.ele Telethon Institute for Gene Therapy, Via Olgettina, 58, Milan 20132, Italy. Fax: +39 02 26434668.
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249Hyperproliferation in IPEX-like CD25null patientThus, the complex pathogenesis of CD25 deficiency provides invaluable insight into the role of
IL2/IL-2RA-dependent regulation in autoimmunity and inflammatory diseases.© 2013 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
The interleukin-2 (IL-2) receptor is formed by the α (IL-2RA,
CD25) [1], β (IL-2RB, CD122) [2] and γcommon (IL-2RG, CD132)
[3] subunits, and plays a vital role in maintaining the immune
system. Among the IL-2 receptors, CD25 is a unique subunit
that exclusively binds IL-2, while CD132 binds the common γc
family cytokines (IL-4, IL-7, IL-9, IL-15 and IL-21), and the
CD122 subunit binds IL-15. CD25 is constitutively expressed at
high levels by CD4+CD25+FOXP3+ regulatory T cells (Tregs),
and enables them to be the first responders to IL-2 during an
immune response [4] and promotes the transcription of FOXP3
by amplifying IL-2 signaling in a STAT5-dependent fashion [5].
Interestingly, single nucleotide polymorphism (SNP) studies of
the IL2RA gene have been associated with several forms of
autoimmunity [6–10] demonstrating that IL-2 signaling via
CD25 is an important axis in regulating tolerance. CD25 is
also critical for effector T cell expansion in response to
IL-2 immediately after antigenic stimulation. Although
both CD4+ and CD8+ T cells up regulate CD25 and IL-2RB
upon activation, CD8+ T cells are more susceptible to IL-2
stimulation, probably due to their higher level of IL-2RB
expression both in mice [11] and humans [12,13].
The immunological consequence resulting from the loss of
CD25 has been ill-defined in man. Roifman's group was
the first to describe a CD25 deficient patient who suffered
from chronic infections and severe autoimmunity [14] resem-
bling Immune dysregulation, Polyendocrinopathy, Enteropathy,
X-linked (IPEX) syndrome, caused by mutations in FOXP3 gene
[15]. This IPEX-like patient possessed a translation frameshift
mutation in the IL2RA gene ablating its expression. Similarly, a
second report described a patient with a different frameshift
mutation in the IL2RA gene leading to a CD25 null phenotype
with comparable clinical manifestations [16].
Here we describe the immunological findings of a patient
carrying an IL2RAmutation not previously reported, selectively
abrogating CD25 cell surface expression. Our results show, for
the first time in human, the complex immunopathology
associated with CD25 deficiency, and reveal a distinct patho-
genetic mechanism of immune dysregulation.2. Material and methods
2.1. IL2RA molecular analysis
Genomic DNA was extracted from peripheral blood mono-
nuclear cells (PBMCs) using the QIAamp DNA Blood Mini Kit
(Qiagen, Valencia, CA) according to the manufacturer's
recommendations. PCR for each of the 8 exons of the
human IL2RA gene (including exon/intron boundaries) was
performed using PCR techniques as previously reported [17] andsequence conservation analysis of mutations was performed
using PolyPhen, SIFT and SNPs3D tools.
2.2. Flow cytometry
PBMCs were isolated using Lymphoprep (Axis-shield) density
gradient centrifugation. Surface Ab staining was performed
for 30 min on ice in the absence of light using a 2% bovine
serum albumin PBS mixture. Cells were washed and fixed with
either 2% paraformaldehyde (Pierce) for later acquisition or
with FOXP3 perm/fix buffer (eBioscience) to be further
stained for FOXP3 or Ki67 The following Abs (all antibodies
purchased from BD Biosciences unless otherwise noted): CD4
(SK3), CD8 (SK1), CD25 (2A3; M-A251), CD45RA (HI100), CD49d
(L25), CD62L (SK11), CD69 (FN50), CD122 (MIKB2), CD132
(TUGh4), Ki67 (B56), FOXP3 (eBioscience PCH101), HLA-DR
(L243), FASL (NOK-1), and HELIOS (22F6) (Biolegend).
2.3. T cell line generation and stimulation
Healthy donor cell lines were generated by stimulating
1×106 PBMCs with PHA 1 μg/ml (Sigma) in X-Vivo media
(Biowhitaker) containing 5% human serum (Biowhitaker),
1% penicillin and streptomycin (Lonza), IL-2 (40 U/ml,
Proleukin (Novartis)). On days 9, 14 and 20 the cells were
washed and plated in the presence of IL-2 (100 U/ml), IL-7
(10 ng/ml), and IL-15 (10 ng/ml). For the CD25 deficient
patient, CD4+ T cells were enriched using CD4+ T cell
negative selection beads (Miltenyi) and cultured with IL-2
(100 U/ml), IL-15 (10 ng/ml), IL-7 (10 ng/ml). Cells were
washed and restimulated with the same conditions on days
7, 11, and 20. On day 24, cells were washed and stimulated
in 24 well plates (Corning) containing plate bound anti-CD3
(10 μg/ml) (BD Pharmingen) and anti-CD28 (1 μg/ml) (BD
Pharmingen) in the presence or absence of IL-2 (100 U/ml)
and IL-15 (10 ng/ml) for 6 h.
2.4. Measurement of sCD25
Levels of sCD25 were evaluated using a commercially available
ELISA kit (BD Pharmingen). To measure sCD25 from activated
cells, PBMCs (1×105) were stimulated for 72 h in complete RPMI
(Biowhitaker) with plate-bound anti-CD3 (OKT3) (10 μg/ml)
and soluble anti-CD28 (2 μg/ml) in the presence or absence
of IL-2 (1000U/ml), TPA (Sigma)/Ionomycin (Sigma), or left
unstimulated.
2.5. Phospho flow cytometry
To determine the phosphorylation (p) status of STAT3 and
STAT5 after cytokine stimulation, a barcode technique was
250 K. Goudy et al.employed as previously described [18]. Briefly, fresh PBMCs
were rested overnight before stimulation with IL-2 (Low
10 U/ml, Med 100 U/ml, Hi 1000 U/ml), IL-15 (10 ng/ml), or
IL-10 (10 ng/ml) for 0, 10, or 30 min. At the appropriate
time point, the cells were fixed with 1.6% electron
microscope grade paraformaldehyde (Pierce) for 10 min at
37° and then washed and permeabilized with 100% methanol
(Sigma) for 10 min on ice. After washing, barcoding of the
cells was performed using pacific blue succinimidyl ester
(Invitrogen) suspended in PBS for 30 min. After washing, the
individual wells were pulled into one tube and stained
simultaneously with surface and intracellular-directed anti-
bodies (CD4, CD8, pSTAT3 (pY705, 4/P-STAT3), pSTAT5
(Y694, clone 47) (BD Pharmingen)) for 30 min at room
temperature. All samples were acquired on a FACScanto
flow cytometer (BD Pharmingen).
2.6. Cytokine detection
To quantify cytokine levels in sera and plasma, the Bio-Plex
protein array system was used according to the manufacturer's
protocol. Levels of IL-1β, IL-2, IL-4, IL-6, IL-10, IL-12(p70),
IL-17, TNF-α, and IFN-γ cytokines (BioRad) were analyzed using
the Luminex system (Luminex) and concentrations of each
cytokine were obtained using Bio-Plex Manager version 3.0
software (Luminex).
2.7. Microscopy
Following informed consent, skin biopsies were taken under
local anesthetic and divided for microscopic analysis. For light
microscopy, samples were formalin-fixed, paraffin embedded
and sectioned at 4 μM for staining. Skin biopsies for immuno-
fluorescenceweremounted inOCT compound (Tissue Tek) and
immediately snap-frozen in liquid nitrogen. Cryostat sections
(5 μm) were mounted on to microscopy slides (Fischer) and
air-dried. Slides were stained with: CD8 (1:200), Ki-67 (1:100),
and granzyme B (1:100) (BD Pharmingen). The tissues were
blocked with 2% goat serum for 1 h and washed before
incubating with the antibody for 1 h at 25 °C. The sections
were then washed, mounted with vector shield (Sigma) and
viewed under a Zeiss fluorescent microscope.
2.8. Proliferation assays
Polyclonal stimulation of PBMCs from healthy donors and
the CD25 deficient patient was performed by culturing atFigure. 1 A c.497GNA mutation in the IL2RA gene inhibits surface
of the patient (left panel) showing a G to A substitution at position 4
S166N. Sequence trace of paternal genomic DNA shows a single copy
from 3 independent experiments of CD25 expression on CD4+ T cells
mother and sister and a healthy control (HC) (n=6) as determined b
column) and cytoplasmic (right column) expression of CD25 on T cel
healthy controls (upper histograms) after stimulation with anti-CD3
IL-15 (dotted line) or left untreated (grayed area). Embedded histog
shown. D, Soluble CD25 (sCD25) was measured from the plasma a
controls. E, Representative histograms showing the expression of C
PBMCs of the patient (large histograms) and healthy controls (embe
CD8+ T cells of the patient (each symbol indicates a unique time poin
on PBMCs.2×105 cells per well in duplicate in flat-bottom 96-well
tissue culture plates (Corning) with plate bound anti-CD3
(10 μg/ml) and soluble anti-CD28 (1 μg/ml) in the pres-
ence of IL-2 low (10 U/ml), medium (100 U/ml), high
(1000 U/ml), IL-2 (100 U/ml)+ IL-15 (10 ng/ml), or with
PHA alone (1 ug/ml). Ag-specific responses were mea-
sured using 1×105 PBMCs in 96-well round bottom tissue
culture plates (Corning) containing the respective Ags.
Each antigen (Candida albicans strain CA-2) (1.25×105
spores per well; kindly provided by Dr. L. Romani Perugia,
Italy), Tetanus Toxoid (TT) (5 μg/ml (Enzo)), CMV
(2.5 μg/ml Towne strain; kindly provided by Dr. Chiara
Bonini, Milan, Italy), Varicella zoster (VZV) rod strain
(2.5 μg/ml (Advanced Biotechnology)) and herpes simplex
virus (HSV) MacIntyre strain (2.5 μg/ml (Advanced Bio-
technology)) were cultured with the cells in the presence
or absence of IL-2 (100 U/ml) and IL-15 (10 ng/ml). The
cells were cultured for 3–4 days before pulsing with [3H]
thymidine for 18 h. Plates were harvested and prolifera-
tion was recorded as counts per minute (cpm) using a
gamma counter.
2.9. ELIspot
The frequency of interferon γ (IFNγ) producing cells was
determined by ELIspot (BD Pharmingen) as previously
described [19]. Briefly, 2×105 freshly isolated PBMCs were
stimulated in the presence or absence of attenuated CMV
(2.5 μg/ml Towne strain), IL-2 (100 U/ml), and or IL-15
(10 ng/ml). After 18–20 h of incubation, plates were washed
and developed according to the established protocol. Spots
were counted using an ELIspot reader adjusted to eliminate
background spots (Aoelovis).
2.10. CMV proliferation
CMV-specific proliferative responses of T cells from the
CD25 deficient patient and healthy controls were tested
in vitro. PBMCs (4×106) were harvested from each donor
and were labeled in 5 μM of carboxyfluorescein diacetate
succinimidyl ester (CFSE) as previously described [20]. The
cells were stimulated with live-attenuated CMV (2.5 μg/ml
Towne strain), and/or IL-15 (10 ng/ml) for 5 days before
harvesting. The resulting cells were stained with anti-CD4
and anti-CD8 antibodies and acquired by flow cytometry.
The proliferation was determined by CFSE dilution for the
respective populations indicated by decreasing MFI.and soluble CD25 expression. A, Sequence trace of genomic DNA
97 (down arrow) in exon 4 leading to the amino acid substitution
of the G497A mutation (right panel). B, Representative dot plots
from PBMCs of the CD25 deficient patient, the patient's father,
y flow cytometry. C, Representative histograms of surface (left
l lines were determined for the patient (bottom histograms) and
and anti-CD28 alone (solid line) or in combination with IL-2 and
rams of CD69 expression for the patient and healthy controls are
t 8 different time points from the patient and from 9 healthy
D122 (upper left) and CD132 (lower left) were determined on
dded histograms). The MFI of CD122 and CD132 on the CD4+ and
t) and healthy controls (n=6) was determined using FACS analysis
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252 K. Goudy et al.2.11. Suppression assay
The sensitivity to suppression of CD8+ effector T cells
by Tregs was performed using allogeneic Treg cells as
suppressors. CD8+ T cells were purified from the CD25
deficient patient, the patient's mother and father and a
healthy donor using CD8+ T cell beads (Miltenyi) according
to the manufacturer's protocol (CD8+ T cell purity was
determined to be N95% for all samples), and were labeled
with 5 μM of CFSE. Tregs were isolated from the patient's
mother and father and healthy donors using CD4+CD25+ Treg
isolation kit (Miltenyi) to high purity and were seeded in a 96
well U bottom plate in triplicate at a 0.5:1 ratio (1.25×104
suppressor cells to 2.5×104 responder cells) in complete
X-Vivo (Biowhitaker). The cells were then stimulated with
inspector beads (Miltenyi) using 2 beads per cell in the
presence or absence of IL-2 (100 U/ml) for 5 days. The cells
were then harvested and stained for CD8 to determine the
level of proliferation in each condition.2.12. Statistics
Statistical significance of mean differences for each parameter
was determined by 2-tailed Student's t test or by ANOVA
followed by post-hoc Bonferroni test for multiple comparisons
where appropriate. Data are expressed as mean±SEM, and
a p value less than 0.05 was considered significant. All
calculations were done using GraphPad Prism software ver.5
(GraphPad Software).3. Results
3.1. Case report
The patient is an 8 year-old female born to consanguineous
parents (first cousins) of Italian descent, who developed
symptoms resembling IPEX, such as diffuse eczema and severe
diarrhea, during her first month of life. The enteropathy with
severe villous atrophy was diagnosed as of autoimmune origin
and complicated with CMV infection, which was treated by
Gancyclovir, but became recurrent. The patient suffered from
enteropathy until 5 years of age, often requiring parenteral
nutrition and was treated with continuous combination therapy
of steroids and Tacrolimus or Tacrolimus alone.
At 1 year of age, she developed a bullous pemphigoid as a
reaction to hexavalent vaccination and was treated with
plasmapheresis. She presented an autoimmune thyroiditis at
4 years of age, which was treated with hormone replace-
ment therapy until the thyroiditis resolved at 7 years. She
was constantly treated with immunosuppressive therapy
over all 6 years, but only with partial and transient
benefit. When she was 5 years old, she developed diffuse
eczema and alopecia universalis despite the immunosup-
pressive therapies. The skin lesions became a severe form
of psoriasiform dermatitis, which extended to the whole
body and was characterized by erythroderma and scaling
skin associated with multiple lymphadenopathies of ingui-
nal, axillary, nucal and dorsal lymph nodes, diagnosed as
hyper-reactive lymph nodes by ultrasonographic examination.
During the last year of her follow-up, genital skin lesions werecomplicated by a severe cellulitis caused by Staphylococcus
aureus and Pseudomonas aeruginosa, requiring multiple antibi-
otic therapy. At 8 years and 6 months of age, due to the
evolving dermatitis, Methotrexate was also started with no
benefit. Therefore, Mycophenolate Mophetil was given alone
with limited improvement of skin lesions, but improvement of
the lesions was only seen when combined with rapamycin.
Additional therapies included prophylactic treatment, against
Pneumocystis jiroveci and fungi, and Gancyclovir upon detec-
tion of CMV reactivation. Hematopoietic stem cell transplanta-
tion was indicated as the only curative treatment for the
disease and since the patient did not have a matched family
donor, a search for matched unrelated donors from the Registry
was initiated.
While the patient was in our hospital between the ages
of 8 years and 4 months and 8 years and 9 months, her
WBC (8933/μL±3033; normal range: 5500–15,500/μL), and
total lymphocyte counts (2821/μL±1194; normal range:
2000–8000/μL) were in the normal range. However, the
patient showed an inverted CD4/CD8 ratio (0.8±0.4; normal
range: 0.9–2.6) with normal CD4 counts (1000/μL±341;
normal range 300–1300/μL) and high CD8 counts (1574/μL±
855; normal range 300–1300/μL). In addition, low B (77/μL±
52; normal range 200–1600/μL) and NK (83/μL±72; normal
range: 90–900/μL) cell counts persisted during her stay.
C-reactive protein (CRP) was negative. Serum IgG and IgM were
normal (1150 mg/dL — normal range: 633–1016 mg/dL — and
149 mg/dL — normal range: 56–261 mg/dL, respectively),
while IgA and IgE were elevated (409 mg/dL — normal range:
41–315 mg/dL and N5000 kUA/L — 1.6–60 kUA/L, respec-
tively). Serum analysis showed the presence of protective
titers of IgG anti-Tetanus, anti-Hepatitis B and anti-CMV, while
she did not have anti-Herpes Simplex Virus-1 and anti-Herpes
Simplex Virus-2 antibodies. The screening for celiac disease
was negative. The serum screening for other auto-antibodies
(anti-pancreatic insula (ICA), anti-glutamic acid decarboxylase
(GAD), anti-insulin, anti-IA2, anti-ZNT8, anti-thyroglobulin,
anti-thyroperoxidase, anti-liver kidney microsome (LKM),
anti-adrenal glands, ANA, ENA) was negative. The NK
activity measured as CD107a+ cells in the presence of IL-2
or IL-15 against K562, was preserved (data not shown).
3.2. Novel IL2RA mutation
The molecular analysis of the IL2RA gene of the patient's DNA
revealed the presence of a previously unreported mutation
(Fig. 1A). The patientwas homozygous for a c.497GNA transition
in exon 4, leading to an amino acid substitution at codon 166
(S166N) of the protein. The patient's father (Fig. 1A), mother,
and sister proved to be heterozygous for the same mutation
(data not shown).
3.3. CD25, CD122 and CD132 protein expression
analysis
Immunophenotype analysis of freshly isolated PBMCs from
the patient showed the absence of CD25 expression on
the surface of CD4+ T cells (Fig. 1B). On the other hand,
CD25 was detected on CD4+ T cells of the parents and the
sister of the patient (16%, 14.5%, 13.9% for father, mother,
and sister respectively), although at a lower frequency than
253Hyperproliferation in IPEX-like CD25null patientthe healthy controls (26.7±6.5, n=5), which might be
explained by the patient's kin being heterozygous for the
mutation (Fig. 1B).
CD25 surface expression on CD4+ T cell lines of the patient
remained undetectable upon TCR mediated activation even in
the presence of exogenous IL-2 and IL-15 (Fig. 1C). Control CD4+
T cell lines tested in parallel, showed increased surface CD25
expression. Importantly, TCR activated CD4+ T cells of the
patient expressed CD25 in the cytoplasm, as well as at the
mRNA level (data not shown), in a comparable amount to
the healthy control (Fig. 1C). This raised the question whether
CD25 was rapidly shed from patient's cell surface or remained
intracellular. Soluble CD25 (sCD25) was undetectable in the
sera (Fig. 1D) or in cell supernatants of activated PBMCs
(Supplementary Fig. 1) from the patient compared to healthyFigure. 2 CD25 deficiency promotes a T memory cell phenotype. A
FOXP3+ CD4+ T cells (upper panels), CD127low cells expressing
CD127lowCD49dlow cells expressing FOXP3 (middle bottom panels w
determined in the CD25 deficient patient (average of 2–4 differ
percentage of 2–6 different donors is shown). B, The average percen
CD62L+), effector memory (TEM; CD45RA−CD62L−) for CD4+ (upper ro
healthy controls (right columns). The percentages shown are the ave
six healthy donors. C, The overall percentage of memory cells (CD45R
the effector populations within the memory pool (CD45A−) of the pacontrol samples demonstrating that the IL2RA mutation of the
patient inhibits plasma membrane expression and subsequent
shedding of the CD25 protein.
To evaluate whether other IL-2R subunits were affected by
the loss of CD25 surface expression, CD122 and CD132
expression was determined on CD4+ and CD8+ T cells. In healthy
controls, CD8+ T cells expressed CD122 at higher intensity than
CD4+ T cells as determined by Mean Florescence Intensity (MFI)
(731.7±249.5 and 261.1±121.3, respectively, p=0.0012) but
there was no significant difference in CD132 expression
between CD8+ and CD4+ T cells (497.9±270.4 and 495.7±
308.9, respectively, n=6) (Fig. 1E). Compared to healthy
controls, CD8+ T cells of the patient expressed lower levels
of CD122 (p=0.0127), while, both CD8+ and CD4+ T cells
of the patient expressed significantly higher levels of CD132, Representative FACS plots depicting the average percentage of
FOXP3 (middle upper panels with embedded histograms),
ith embedded histograms), FOXP3+ and HELIOS+ staining were
ent time points is shown) and healthy controls (HC; average
tage of naïve (CD45RA+CD62L+), central memory (TCM, CD45RA−
w) and CD8+ (lower row) T cells for the patient (left column) and
rage of 4 different time points for the patient and the average of
A−) from the patient and healthy controls. D, The percentage of
tient and healthy controls.
Figure. 3 Reduced IL-2 response of T cells from the CD25 deficient patient but FOXP3+ T cells remain first responders. A, The
percentage of CD4+ (upper row) and CD8+ (lower row) T cells from PBMCs of the patient (left column) or healthy controls (right
column; n=5) responding to IL-2lo (10 U/ml), IL-2med (100 U/ml), IL-2hi (1000 U/ml), or IL-15 (10 ng/ml) at 0, 10 or 30 min. pSTAT5
was evaluated by flow cytometry from barcoded cells. B, Representative dot plots of the IL-2 responsiveness of CD4+FOXP3+ and
CD4+FOXP3− T cells from the patient and healthy control were evaluated for using IL-2lo (10 U/ml), IL-2med (100 U/ml), IL-2hi
(1000 U/ml) conditions at the indicated time points determined by pSTAT5. C, The hierarchy of IL-2 signaling was determined from
PBMCs of the patient (left column; closed shapes) or healthy control (right column; open shapes (n=3)) for CD4+FOXP3+, CD4+FOXP3−
and CD8+ T cells in response to different concentrations of IL-2 as used in B.
254 K. Goudy et al.(p=0.0031 and p=0.0175, respectively). These data indi-
cate that, despite the loss of CD25 cell surface expression,
both CD122 and CD132 are still expressed on the patient's T
cells and CD132 expression is elevated in the patient.3.4. Lack of CD25 surface expression does not
interfere with Treg development and is associated
with predominant peripheral memory T cell
phenotype
In the patient, the percentage of FOXP3-expressing CD4+ T
cells was 7.7±5% (n=4 time points), which was comparable
to those of healthy controls (5.7±1.6%, n=19, 7 months toFigure. 4 Abundant innate and adaptive cytokines in vivo correlat
the CD25 deficient patient (unique symbol for each time point) and
measured for innate (A) and adaptive (B) associated cytokines. C, R
pSTAT3 (lower row; bold line) in CD4+ and CD8+ T cells of the C
(embedded histogram) using isotype control antibody staining (gray
from fresh PBMCs were determined by staining for Ki-67+ (represen
and CD8+ T cells from the CD25 deficient patient and healthy contro
students t test). F, Representative histograms of HLA-DR and F
proliferating (Ki-67−; dashed line) CD8+ T cells from the CD25 deficie
healthy controls (dotted lines). Gray line is the staining control on t10 years) (Fig. 2A). This percentage did not seem to change
with the stage of the disease. However, the highest
percentage of CD4+FOXP3+ T cells (14.4%) was detected
within three weeks of rapamycin treatment. We further
characterized the Tregs using other Treg-specific markers
(Fig. 2A). FOXP3 expressing cells were 30.3±12.2 (n=4 time
points) in CD4+CD127low gate for the patient, which were
comparable to healthy control values (22.8±13.6%, n=5).
Additionally, FOXP3-expressing T cells of the patient in
CD4+CD49dlowCD127low gate ranged between 12.5 and 62.1%
(mean: 29.7%, n=4 time points), which was similar to
healthy control values with variability (22.2±6.5%, n=5).
Similarly, the proportion of CD4+ T cells co-expressing
HELIOShi and FOXP3+ showed no disparities with healthye with predominate CD8+ activation and proliferation. Sera from
healthy donors (each symbol represents a unique patient) were
epresentative FACS plots of pSTAT5 (upper row; bold line) and
D25 deficient patient (larger histogram) and healthy controls
ed area) as a reference. D, Proliferating CD4+ and CD8+ T cells
tative FACS plot shown). The average proliferative rate of CD4+
ls (E) was taken at different time points and averaged (p value;
AS-L expression on proliferating (Ki-67+; solid line) and non
nt patient at two different time points or total CD8+ T cells from
he CD8+ T cells.
255Hyperproliferation in IPEX-like CD25null patientcontrols (7.1±4% (n=2 time points) and 6.2±4.5% n=2
respectively), and the expression of CTLA4 and GITR on
FOXP3+ T cells was found at comparable levels (data not
shown). The presence of bona fide Tregs was confirmed atthe molecular level by the analysis of the T-regulatory
cell-specific demethylated region (TSDR) of FOXP3 [21]. To
elucidate the relative proportion of Tregs in the CD3+ T cell
population, we normalized for the percentage of total
256 K. Goudy et al.T-lymphocyte-specific demethylated region (TLSDR) of CD3
[22]. The patient displayed 3.80% of Tregs in CD3+ cell
population, thus under the 25° percentile (b4.21%) of the
normal range (normal values 1.8–8.1%) [23], even if the
percentage of Tregs determined in purified CD4+ T cells by
TSDR demethylation analysis was 13.8%, a value slightly
above those of healthy controls (6.5–12.2%, median: 7.5%,
n=7, 3 months to 13 years). Overall these results indicated
that peripheral Tregs were present in the patient despite the
absence of a functional CD25, albeit at an overall reduced
level in total lymphocytes.
Further characterization of peripheral T cells showed
increased CD45RA− memory CD4+ (92.5±1.6%) and CD8+
(87.5±3.6) T cells in the patient (n=4 time points; Figs. 2B
and C) compared to adult normal donors and to memory T
cell values for age (CD4+ T cell memory: 24.0–43.4%; CD8+ T
cell memory: 13.4–29.9%, [24]). Within the increased CD4+
memory T cell populations, CD45RA−CD62L+ central memory
(TCM) cells were predominant over CD45RA−CD62L− effector
memory (TEM) phenotype (Fig. 2D). CD4+ TCM and TEM cells
of the patient showed a distribution pattern similar to those
of healthy controls; however, the patient had a greater
proportion of CD8+ TCM cells in CD8+ in the memory T cell
population. These results indicated that IL2RA mutation in
the patient led to predominant memory phenotype of both
peripheral CD4+ and CD8+ T cells, with significant increase in
CD8+TCM cells proportionally.
3.5. High doses of exogenous IL-2 are required to
induce STAT5 signaling in CD25 null T cells while
FOXP3+CD4+ Tregs remain the first responders
CD25 is a fundamental part of the high affinity IL-2R complex.
To demonstrate that CD25 surface expression confers the
ability of CD4+ T cells to respond rapidly to IL-2, phosphory-
lated (p) STAT5 was determined in CD4 T cells expressing
different levels of CD25 in healthy donors: CD25 high
(CD25hi), CD25+FOXP3+(which includes Tregs), CD25 medium
(CD25med) and CD25 negative (CD25−) (Supplementary
Fig. 2). The level of pSTAT5 was consistent with the intensity
of CD25 expression. In the presence of IL-2 at low con-
centrations, CD4+CD25hi and CD4+CD25+FOXP3+ T cells had
the highest percentage of pSTAT5+ cells while CD4+CD25med
T cells were intermediate responders and CD4+CD25−
responded poorly. Responses to increasing levels of IL-2
concentrations did not alter the sensitivity of each popula-
tion to IL-2. Thus, this data demonstrates that high
expression of CD25, including in FOXP3+ Treg, equips CD4+
T cells to respond preferentially to low levels of IL-2 and have
a higher potential to signal through STAT5.
Since the patient's cells did not express CD25 on their
surface, signaling through the intermediate affinity IL-2R
(CD122 and CD132) was questioned. T cells from the CD25
null patient were tested for their ability to induce pSTAT5 in
response to IL-15 and IL-2 (Fig. 3A). The patient's CD4+ and
CD8+ T cells displayed a pSTAT5 pattern similar to healthy
controls (n=3) in the presence of IL-15, but with a slight
decrease at all time points (10 and 30 min). These data
demonstrate that in the absence of cell surface CD25, CD122
and CD132 are functional in the patient's T cells. To the
contrary, CD4+ T cells of the patient had dramaticallyreduced pSTAT5 at all concentrations of IL-2 tested. CD4+ T
cells of healthy controls (n=3) induced pSTAT5 at all time
points with IL-2 stimulation in a time and dose dependent
manner, while the patient's CD4+ T cells responded only
to the high concentration of IL-2. Overall, the percentages
of pSTAT5+ CD4+ T cells from the patient, even stimulated
at high concentrations of IL-2, were lower than those of
healthy controls (n=3), indicating an overall defect in IL-2
signaling in CD4+ T cells. CD8+ T cells of the patient were less
affected by the loss of CD25 in response to IL-2 stimulation.
The pSTAT5 levels in the patient's CD8+ T cells with high
concentration of IL-2 were similar to the percentages of
CD8+ T cells of healthy controls stimulated with high and
medium concentrations. Together, these data show that
CD4+ T cells from CD25 null patients are more affected
than CD8+ T cells in response to IL-2 when CD25 surface
expression is absent. The alteration in responsiveness results
in the patient's CD8+ T cells becoming more reactive to IL-2
than CD4+ T cells at the medium doses tested.
The comparison of STAT5 signaling in CD4+FOXP3+ and
FOXP3− T cells of the CD25 null patient versus normal
donors shows that neither CD4+FOXP3+ nor CD4+FOXP3− T
cells of patient responded to low concentration of IL-2
(Fig. 3B). Both CD4+FOXP3+ and CD4+FOXP3− T cells had
pSTAT5 detection with medium and high concentration of
IL-2 in a time and dose dependent manner (Fig. 3B).
However, pSTAT5 levels in the patient's cells never reached
those of healthy controls. Importantly, as seen in healthy
controls, pSTAT5 response in CD4+FOXP3+ T cells was always
higher than CD4+FOXP3− T cells. This indicated that even
though CD4+FOXP3+ T cells lacked CD25 expression, they
were able to transmit IL-2 signaling with medium and high
IL-2 stimulation. Therefore, they were still the first CD4+ T
cell subtype responding to IL-2, and their pSTAT5 status was
always higher than CD4+FOXP3− T cells.
The IL-2 signaling hierarchy of CD4+FOXP3+, CD4+FOXP3−
and CD8 T cells was also evaluated. In the CD25 null patient
and in healthy donors, CD4+FOXP3+ T cells were always the
highest responders to IL-2 in all conditions (Fig. 3C). The
percentage of pSTAT5 in CD25 null CD8+ T cells was always
higher than CD4+FOXP3− T cells in intermediate and high
concentrations of IL-2, whereas the CD8+ T cells of healthy
donors had significant levels of pSTAT5 only in the presence
of high doses of IL-2 (Fig. 3C). This data indicates that in the
absence of CD25 surface expression 1) the threshold
required for IL-2 signaling in all T cell subsets is raised, 2)
CD4+FOXP3+ are the first to respond to IL-2 despite the
absence of CD25, and 3) unlike in healthy donors, CD8+ T
cells from CD25 null patients preferentially respond to IL-2
compared to CD4+FOXP3−.
3.6. High serum cytokine levels associate with pSTAT5
and pSTAT3, hyperproliferation, and activation of
CD25 null T lymphocytes in vivo
To determine why the CD25 null patient had high circulating
T lymphocytes, cytokine levels were evaluated in serum. All
cytokines tested, innate immune (IL-6, IL-1β, IL-12p70)
(Fig. 4A) and Th1 (IL-2, IFNγ), Th2 (IL-4, IL-5, IL-10), Th17
(IL-17), and TNFα (Fig. 4B) were above that of age-matched
control, tested over a period of nine months in the presence
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demonstrates that the production of all cytokines tested
was not impaired despite the absence of CD25 surface
expression, suggesting that high cytokine levels found in
circulation may sustain proliferation in vivo. To determine if
CD25 null T cells are activated by the cytokines in vivo,
freshly isolated peripheral CD4+ and CD8+ T cells of the
patient were first evaluated for active STAT5 and STAT3
signaling (Fig. 4C). pSTAT5 levels in CD4+ T cells (72.8 MFI)
and in CD8+ T cells (85.9 MFI) of CD25 null patient (59.8 MFI
and 49.8 MFI, n=2 time points) were higher than in healthy
controls (44.4 MFI and 47.3 MFI, n=2). Similarly, both
CD4+ and CD8+ T cells possessed higher levels of pSTAT3
(217.1 MFI and 127.9 MFI respectively) than healthy controls
(35.2 MFI and 77.4 MFI, n=2; 20.4 MFI and 45.4 MFI, n=2,
respectively). This data indicates that cytokine signaling
pathways in circulating T lymphocytes of the CD25 null
patient had active in vivo signaling to both STAT3 and STAT5
pathways.
Additionally, we found that peripheral CD8+ and CD4+ T
cells of the patient were highly proliferative in vivo as
evident by the expression of Ki-67 (Figs. 4D–E). Ki-67
expression ranged between 8.2 and 35.5% (n=8) in CD8+ T
cells which was significantly higher than healthy control
levels (1.22±0.45%, n=6) at all different time points evaluated
(p=0.0005). CD4+ T cells did not always express Ki-67 at high
levels (0.7–9.7%, n=8), but overall Ki-67 expression was
increased compared to healthy control values (1.28±0.43%,
n=6), (p=0.03). Importantly, an increase in Ki-67 expression
was more prominent in CD8+ T cells than CD4+ T cells for all
time points detected (p=0.0036). Although Ki-67 expression
remained high in CD8+ T cells the lowest point was during
rapamycin treatment. Both proliferating and non-proliferating
CD8+ T cells had high surface expression of HLA-DR (86% and
90.1%, n=2; 85% and 75.2%, n=2, respectively) and FAS-L on the
cell surface consistent with the highly activated phenotype of
CD8+ T cells (87.6% and 96.3%, n=2; 88.4% and 95%, n=2,Figure. 5 Epidermal hyperplasia due to CD8+ T cell infiltration, proli
showed hyperplasiawith hyper-orthokeratosis. (B), Lymphocytic infiltrat
phenotype (CD3+). Skin infiltrating cells were mostly CD8+ T cells
immunofluorescence staining with CD8 and Ki-67 (E). F, A high frequencrespectively) (Fig. 4F). However, BCL-2 expression, an
anti-apoptotic protein, was low in proliferating CD8+ T cells
(40.7% and 52.1%, n=2) but comparable to healthy donors in
non-proliferating cells (data not shown). Irrespective of the
BCL-2 levels, T cells from the CD25 deficient patient were not
prone to apoptosis compared to healthy donors (data not
shown). Decreased BCL-2 expression in proliferating peripheral
CD8+ T cells and increased FAS-L expression in highly activated
CD8+ T cells suggest that intrinsic and extrinsic apoptotic
pathways in CD8+ T cells were not disrupted in the patient
carrying CD25 mutation.3.7. Proliferating CD8+ T cells mediate autoaggression
in skin
The morphological analysis of skin biopsy of the patient's,
epidermis showed hyperplasia with hyper-orthokeratosis
(Fig. 5A). A dense small to medium lymphocytic infiltrate
was observed mainly in upper dermis (Fig. 5B). Infiltrating
lymphocytes almost exclusively displayed a T cell pheno-
type (CD3+) (Fig. 5C), while B-cells (CD20+) were occasion-
ally encountered, and staining for immunoglobulins was
negative (data not shown). T cells were almost invariably
CD8+ (Figs. 5D–F). Many of these skin infiltrating CD8+ T
cells were proliferating as determined by double immuno-
fluorescence staining with Ki-67 (Fig. 5E). Additionally,
they were granzyme B+ (GrzB+) CD8+ T cells (Fig. 5F).
TCR rearrangement assessed by PCR both on skin biopsy and
peripheral blood revealed a polyclonal T-cell population
(data not shown). These data show that CD8+ T cells
highly infiltrate the skin, undergo proliferation, and present
lytic capacity, suggesting that CD8+ T cells are mediating
skin aggression manifesting as severe erythrodermia.
However, the CD8+ T cells display normal sensitivity to
suppression when co-cultured with Tregs from normal
donors (Supplementary Fig. 3).feration and granzyme B production. A, A skin biopsy of the patient
ewas observedmainly in upper dermis, (C) displayingmostly a T cell
(D–F) and many were proliferating as determined by double
y of CD8+ T cells was also granzyme B+.
Figure. 6 Defective T cell responses to polyclonal mitogens and viral Ags. A, PBMC from the patient and healthy controls were
stimulated with anti-CD3 and anti-CD28 in the presence or absence of IL-2 (+ 10 U/ml, ++ 100 U/ml, and +++ 1000 U/ml) and/or IL-15
(10 ng/ml) and/or IL-15 (10 ng/ml), or PHA and proliferation was determined by 3H-thymidine after 3 days. B, T cell responses to C.
albicans, TT, were measured after 4 days and (C) different viruses (CMV, VZV, and HSV) were measured after 3 days of stimulation in
the presence or absence of IL-2 and IL-15. D, PBMC ELIspot assays from the patient and healthy control were stimulated with CMV Ags
alone or in the presence of IL-2 or IL-15, or with IL-2, IL-15, or TPA/Ionomyocin alone.
258 K. Goudy et al.3.8. In vitro proliferation defect to polyclonal
mitogens was rescued with exogenous IL-2, but
viral-specific response was consistently absent
One of the main clinical manifestations of the patient,
other than autoimmunity,was chronic viral infections especially
CMV. We tested the ability of the patient's PBMCs to respond
to Ag-specific and non-specific TCR activation. The patient's
PBMCs had poor in vitro proliferation response to TCR-mediated
activation compared to healthy controls (Fig. 6A), which was
partially rescued by exogenous IL-2 and IL-15. T cell responses
to C. albicans, Tetanus Toxoid (TT), and different viruses (CMV,
VZV, and HSV) were also impaired (Figs. 6B–C). Similarly, the
patient's PBMCs did not produce IFNγ upon CMV activation, as
determined by ELISPOT assay. The addition of high concentra-
tions of IL-2 or IL-15 did not rescue IFNγ production (Fig. 6D) or
CD4 or CD8 CMV-specific proliferation (Supplementary Fig. 4).
These results demonstrate that T cells from the CD25 null
patient poorly respond to polyclonal mitogens and to microbial
and viral Ags despite the persistent in vivo exposure to CMV.
4. Discussion
Studies of primary immunodeficiencies have been fundamental
in defining the function(s) of specific molecules in healthand disease. The present work represents a detailed study
on the immunological status of a patient lacking CD25 surface
expression due to a novel point mutation. The chronic effect
of this mutation led to the development of progressive
manifestations of both autoimmunity, such as enteropathy,
erythrodermia and severe alopecia, and immunodeficiencywith
chronic CMV infection. Profound alterations of the peripheral T
cell subsets consisted of a complete skew towards increased
CD8+ T cells over CD4+ T cells, expansion of the memory T cell
compartments, with preservation of FOXP3+ T regulatory cells,
whereas B cells and NK cells were persistently low. Increased
expression of T cell activation markers and high serum levels of
innate and adaptive cytokines were detected in parallel with
high in vivo proliferation of T cells. Despite the lack of surface
CD25, both Tregs and T effector cells remained able to respond
to cytokines, although impaired in their sensitivity to IL-2, as
demonstrated by pSTAT5. Among the peripheral T effector
cells, CD8+ T cells of the CD25 deficient patient highly
expressed CD132, and this increased expression made them
more responsive to IL-2 than CD4+ T effector cells. Proliferating
CD8+ GrzB+ T cells aggressively infiltrated the skin, suggesting
that they were the main mediators of the tissue damage.
However, Ag-specific T cell responses were deeply impaired
in vitro and in vivo. Therefore, these data demonstrate that the
persistent lack of CD25 surface expression hinders the develop-
ment of effective Ag-specific T cell responses while cytokine
259Hyperproliferation in IPEX-like CD25null patientdriven polyclonal T cell proliferation and activation mediate
tissue damage.
Similar to the reported CD25 deficient cases, CMV infection
and severe early onset enteropathy were the first signs of the
deficiency in the patient studied [14,16]. The failure to resolve
CMV infection in CD25 deficient patients and other primary
immunodeficiencies, could logically explain a skewed CD4/CD8
T cell ratio. Since CMV infection induces innate immune
responses and leads to the expansion of CMV-specific effector
T cells, one would predict that the expansion of the CD8+ T cell
compartment in CD25 deficient patients is due to the response
to CMV Ags [25]. Surprisingly, the patient's T cells responded
poorly to viral, bacterial and fungal Ags. T cell exhaustion and
increased sensitivity to apoptosis were ruled out as possible
causes for decreased Ag-specific responsiveness (data not
shown). The impairment of effector functions by the CD8+
T cells could be due to the lack of CD25 during priming. Bevan's
group demonstrated in mouse that CD25 expression during
a primary immune response is critical for programming
protective memory cells to respond to Ag during re-exposure
[26]. Thus, the absence of surface CD25 expression in the
patient presumably impairs the induction of effective
Ag-specific memory T cell responses thus explaining
the patient's inability to clear infections. In addition,
the reported dysfunction of CD25 deficient dendritic cells
could contribute to ineffective Ag presentation and T cell
activation [27]. It is tempting to speculate that the
persistent infections (i.e. CMV) and the innate immune
responses thereof, act in concert to promote non-specific
CD8+ T cell proliferation probably as a result of the accumula-
tion of the numerous cytokines like the ones found in the serum
of the patient. Indeed, based upon our findings, CD25 deficiency
altered the hierarchical signaling in response to IL-2 in favor
of CD8+ T cells over the CD4+ T cells, contrary to what is
observed in healthy subjects. This switch in IL-2 sensitivity
together with increased IL-2 levels in serum could be the driving
force in the expansion of CD8+ T cells in the absence of cell
surface CD25 expression. Supporting this notion are studies
performed in the CD25 KO mouse model that showed that the
progressive expansion of memory CD8+ T cells is IL-2 driven
[28,29].
Treg cells are clearly present in CD25 deficient patients. In
line with the Verbsky study showing the presence of
CD4+FOXP3+ cells [16], we detected a normal frequency of
CD4+FOXP3+ Tregs that also had a similar phenotype to Tregs
from normal donors (CD127LOCD49d−HELIOS+CTLA4+GITR+).
However, we demonstrate that the proportion of bona fide
Tregs with demethylated TSDR was low when normalized to the
whole lymphocyte compartment. These findings are consistent
with the possibility that CD25 is not necessary for FOXP3+
Treg development in humans, but suggest that in the absence of
CD25, Tregs remain quantitatively insufficient for an appropri-
ate regulation. Interestingly, CD25 null FOXP3+ Tregs from
the patient were still the first to respond to IL-2 (in vitro) albeit
at higher concentrations than required by healthy subject
Tregs. Likely, the most affected function due to CD25
deficiency by FOXP3+ Tregs is the consumption of IL-2. Indeed,
upon adoptive transfer of CD25+ FoxP3+ Tregs into CD25
knockout mice, IL-2 levels were dramatically reduced, normal
CD4+ and CD8+ T cell ratios were restored and the memory
phenotype of both CD4+ and CD8+ T cells returned to
near normal levels [28]. Together this indicates that IL-2consumption by FOXP3+ Tregs is a critical event to maintain
the homeostasis of the immune system, and the loss of CD25
surface expression by FOXP3+ Tregs in CD25 deficient patients is
likely a contributing factor in the preferential CD8+ T cell
proliferation, which are the mediators of autoimmunity.
Whether the tissue aggression by CD8+ T cells is auto-Ag driven
remains to be clarified. However, the observation that the TCR
repertoire of the proliferating T cells is polyclonal argues
against it.
Even if CD25 deficiency is considered similar to IPEX
syndrome, we clearly highlight major differences in
the pathogenesis of the two diseases. Indeed, in IPEX
lymphoproliferation involves mainly CD4+ T cells and it is
mainly due to loss of regulation by intrinsically dysfunc-
tional FOXP3mut Treg rather than being cytokine driven
[30,31]. In the serum of IPEX patients, cytokines are not
particularly elevated and Th2 rather than Th1 cytokines are
detectable together with increased IL-17 and IL-22, directly
related to autoimmunity [32]. In addition, effective immune
response to pathogens is preserved in IPEX in which
infections mostly occur as secondary to poor clinical con-
ditions or drug dependent immunosuppression. Similarly,
autoAb are not readily detectable in CD25 null patients. We
therefore demonstrated that even though similarities exist,
the pathophysiology of autoimmunity in CD25 deficiency
is mechanistically distinct from that of IPEX syndrome,
and also from that observed in other monogenic primary
immunodeficiencies with autoimmunity, such as Omenn's syn-
drome, Wiskott–Aldrich or Autoimmune Lymphoproliferative
syndrome (ALPS) due respectively to altered thymic deletion
of autoreactive T cells, impaired cytoskeleton re-organization
during activation of multiple cell type including Tregs [33,34]
or defective apoptosis [35].5. Conclusion
In conclusion, we show that CD25 expression is required to
maintain immune homeostasis, and CD25 deficiency is a
distinct immunological disease that leads to both an
autoimmune and immunodeficiency syndrome that clini-
cally resembles IPEX syndrome. Furthermore, CD25 ex-
pression is necessary in human T cells in order to establish
a signaling paradigm where IL-2 is utilized in an ordered
fashion, and alterations to the hierarchical signaling
events can lead to the loss of immune homeostasis. The
proposed concept that the failure to properly consume
IL-2 and lack of optimal IL-2 signaling contributes to the
development of autoimmunity in CD25 deficient patients,
could be extended to different autoimmune pathologies in
which a reduced CD25 expression occurs as the result of
single nucleotide genetic variants of CD25 or of other
molecules interfering with proper CD25 signaling. More in
depth studies aimed at clarifying this possibility are
desirable.Conflict of interest statement
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